Arcturus Therapeutics: B. Riley Praises the Modified Lipid-Based RNA Platform and Sees Approximately 230% Price Potential

Revolutionary mRNA Technology for Rare Genetic Defects Arcturus Therapeutics (ARCT) positions itself as a commercial biotechnology company dedicated to the development of advanced messenger RNA (mRNA) therapeutics. From the company's perspective, the focus is on offering novel solutions to patients with rare, life-threatening liver and respiratory diseases for which there are currently few effective or causal therapies. At the core of its offering is a proprietary platform based on the so-called LUNAR lipid nanoparticle technology for targeted...